[{"id":"2a6d7e4f-c35c-4e6b-8dc6-72106bb36c61","acronym":"","url":"https://clinicaltrials.gov/study/NCT04750954","created_at":"2023-12-06T16:15:46.614Z","updated_at":"2025-02-25T13:53:37.832Z","phase":"Phase 1","brief_title":"Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors","source_id_and_acronym":"NCT04750954","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e peposertib (M3814) • Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 07/22/2021","start_date":" 07/22/2021","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2025-02-20"},{"id":"13a8ea63-40e9-404c-b670-688e9b2c8b54","acronym":"LuDO-N","url":"https://clinicaltrials.gov/study/NCT04903899","created_at":"2021-05-27T13:53:06.417Z","updated_at":"2025-02-25T15:26:53.866Z","phase":"Phase 2","brief_title":"177Lutetium-DOTATATE in Children with Primary Refractory or Relapsed High-risk Neuroblastoma","source_id_and_acronym":"NCT04903899 - LuDO-N","lead_sponsor":"Jakob Stenman","biomarkers":" SSTR • CD34 • SSTR2","pipe":" | ","alterations":" SSTR2 expression • SSTR Expression","tags":["SSTR • CD34 • SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 expression • SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 05/19/2021","start_date":" 05/19/2021","primary_txt":" Primary completion: 05/20/2026","primary_completion_date":" 05/20/2026","study_txt":" Completion: 05/20/2031","study_completion_date":" 05/20/2031","last_update_posted":"2025-02-11"},{"id":"470be808-bc58-41ba-9198-bd615bd2748f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04711135","created_at":"2021-02-11T16:55:42.049Z","updated_at":"2024-07-02T16:34:25.979Z","phase":"Phase 2","brief_title":"Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs","source_id_and_acronym":"NCT04711135","lead_sponsor":"Advanced Accelerator Applications","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 08/31/2022","start_date":" 08/31/2022","primary_txt":" Primary completion: 03/12/2024","primary_completion_date":" 03/12/2024","study_txt":" Completion: 05/07/2029","study_completion_date":" 05/07/2029","last_update_posted":"2024-06-14"},{"id":"2d466bac-cc21-4880-9a02-9ce432c80a1e","acronym":"ETCTN 10388","url":"https://clinicaltrials.gov/study/NCT04234568","created_at":"2023-12-06T21:16:22.996Z","updated_at":"2024-07-02T16:34:26.307Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors","source_id_and_acronym":"NCT04234568 - ETCTN 10388","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Triapine (3-AP)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 07/20/2020","start_date":" 07/20/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-13"},{"id":"0a7abb08-ccb1-4e69-80bd-9e92b2a533e2","acronym":"NETTER-2","url":"https://clinicaltrials.gov/study/NCT03972488","created_at":"2021-02-11T16:53:55.907Z","updated_at":"2024-07-02T16:35:03.576Z","phase":"Phase 3","brief_title":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","source_id_and_acronym":"NCT03972488 - NETTER-2","lead_sponsor":"Advanced Accelerator Applications","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • octreotide acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 226","initiation":"Initiation: 01/22/2020","start_date":" 01/22/2020","primary_txt":" Primary completion: 07/20/2023","primary_completion_date":" 07/20/2023","study_txt":" Completion: 10/29/2027","study_completion_date":" 10/29/2027","last_update_posted":"2024-05-15"},{"id":"788d5186-c5e0-4cdd-ba52-51d8b5d8095b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04544098","created_at":"2021-02-11T16:55:22.383Z","updated_at":"2024-07-02T16:35:06.529Z","phase":"Phase 1","brief_title":"Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver","source_id_and_acronym":"NCT04544098","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive • SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive • SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 09/02/2020","start_date":" 09/02/2020","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-05-02"},{"id":"23956507-6f6e-456a-86d1-530788914d8c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05410743","created_at":"2022-06-08T11:58:16.092Z","updated_at":"2024-07-02T16:35:09.466Z","phase":"Phase 1","brief_title":"Evaluatioon of 177Lu-TATE-EB-01（LNC1010）in SSTR2-positive Tumors","source_id_and_acronym":"NCT05410743","lead_sponsor":"The First Affiliated Hospital of Xiamen University","biomarkers":" SSTR • FAP","pipe":" | ","alterations":" SSTR positive • SSTR Expression","tags":["SSTR • FAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive • SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 177Lu-LNC1010"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-04-16"},{"id":"0e0834be-0c1a-4cc9-89e5-a3e0950833c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04082520","created_at":"2021-02-11T16:54:03.522Z","updated_at":"2024-07-02T16:35:12.274Z","phase":"Phase 2","brief_title":"Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy","source_id_and_acronym":"NCT04082520","lead_sponsor":"Mayo Clinic","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 04/08/2020","start_date":" 04/08/2020","primary_txt":" Primary completion: 09/04/2024","primary_completion_date":" 09/04/2024","study_txt":" Completion: 09/04/2025","study_completion_date":" 09/04/2025","last_update_posted":"2024-03-29"},{"id":"e6ad9910-26f5-478f-813c-389648b33623","acronym":"SCARLET","url":"https://clinicaltrials.gov/study/NCT04379817","created_at":"2021-02-11T16:55:05.338Z","updated_at":"2024-07-02T16:35:12.200Z","phase":"Phase 2","brief_title":"Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients","source_id_and_acronym":"NCT04379817 - SCARLET","lead_sponsor":"Jules Bordet Institute","biomarkers":" SSTR • SSTR2","pipe":" | ","alterations":" SSTR Expression • SSTR2 positive","tags":["SSTR • SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression • SSTR2 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 02/25/2020","start_date":" 02/25/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-03-29"},{"id":"27145ff7-4899-4e16-a0c3-153894083c4d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05475210","created_at":"2022-07-26T17:10:16.861Z","updated_at":"2024-07-02T16:35:15.078Z","phase":"Phase 1","brief_title":"177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors","source_id_and_acronym":"NCT05475210","lead_sponsor":"Molecular Targeting Technologies, Inc.","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 177Lu-EBTATE"],"overall_status":"Recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 06/18/2022","start_date":" 06/18/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 03/30/2025","study_completion_date":" 03/30/2025","last_update_posted":"2024-03-13"},{"id":"35e34361-ae0b-4c69-8d47-4171b1f9736a","acronym":"PROMENADE","url":"https://clinicaltrials.gov/study/NCT04997317","created_at":"2021-08-09T13:53:17.457Z","updated_at":"2024-07-02T16:35:15.190Z","phase":"Phase 1","brief_title":"Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide","source_id_and_acronym":"NCT04997317 - PROMENADE","lead_sponsor":"University Hospital, Basel, Switzerland","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SOMther (lutetium-177 DOTA satoreotide) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 04/21/2021","start_date":" 04/21/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-12"},{"id":"45acda49-4eea-4ad8-bb32-a2e6799876f3","acronym":"START-NET","url":"https://clinicaltrials.gov/study/NCT05387603","created_at":"2022-05-24T12:54:25.088Z","updated_at":"2024-07-02T16:35:15.531Z","phase":"Phase 3","brief_title":"Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.","source_id_and_acronym":"NCT05387603 - START-NET","lead_sponsor":"Lund University Hospital","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • Solucin (177Lu-edotreotide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2024-03-08"},{"id":"b7112b1e-f06b-4a2d-9f1a-88e7a67281a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04847505","created_at":"2021-04-19T12:52:35.288Z","updated_at":"2024-07-02T16:35:20.517Z","phase":"Phase 3","brief_title":"68Ga-DOTA-TATE PET/CT Imaging in NETs","source_id_and_acronym":"NCT04847505","lead_sponsor":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 01/01/2020","start_date":" 01/01/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-02-07"},{"id":"f3a5cb60-b3cf-4eab-89fc-37e67bbece29","acronym":"","url":"https://clinicaltrials.gov/study/NCT05249114","created_at":"2022-02-21T13:52:47.927Z","updated_at":"2025-02-25T15:54:22.980Z","phase":"Phase 1","brief_title":"Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors","source_id_and_acronym":"NCT05249114","lead_sponsor":"Providence Health \u0026 Services","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 12/28/2022","start_date":" 12/28/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-01-25"},{"id":"83a011cc-3ed7-453f-8d6a-4bfef59bfc3f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03583528","created_at":"2021-01-18T17:37:43.597Z","updated_at":"2024-07-02T16:35:22.583Z","phase":"","brief_title":"DOTATOC PET/CT for Imaging NET Patients","source_id_and_acronym":"NCT03583528","lead_sponsor":"British Columbia Cancer Agency","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive • SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive • SSTR Expression"],"overall_status":"Recruiting","enrollment":" Enrollment 800","initiation":"Initiation: 07/11/2018","start_date":" 07/11/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-01-23"},{"id":"2ce71cc8-c99e-442e-ada8-43ed288e9bdb","acronym":"","url":"https://clinicaltrials.gov/study/NCT06121271","created_at":"2023-11-07T16:14:39.298Z","updated_at":"2024-07-02T16:35:26.861Z","phase":"Phase 2","brief_title":"Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications","source_id_and_acronym":"NCT06121271","lead_sponsor":"University College, London","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive • SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive • SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 12/18/2023","start_date":" 12/18/2023","primary_txt":" Primary completion: 11/06/2027","primary_completion_date":" 11/06/2027","study_txt":" Completion: 11/06/2027","study_completion_date":" 11/06/2027","last_update_posted":"2023-12-07"},{"id":"0b3988e0-808e-4e64-be5c-7766bb2ec569","acronym":"","url":"https://clinicaltrials.gov/study/NCT04804371","created_at":"2021-03-18T12:53:03.098Z","updated_at":"2024-07-02T16:35:41.854Z","phase":"","brief_title":"Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 \u0026 G3 Gastroenteropancreatic Neuroendocrine Tumors","source_id_and_acronym":"NCT04804371","lead_sponsor":"University Health Network, Toronto","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/04/2021","start_date":" 03/04/2021","primary_txt":" Primary completion: 02/22/2024","primary_completion_date":" 02/22/2024","study_txt":" Completion: 02/22/2024","study_completion_date":" 02/22/2024","last_update_posted":"2023-07-27"},{"id":"cb4e3e66-44bd-403d-8c6f-c29c6cdfb963","acronym":"REAL-LU","url":"https://clinicaltrials.gov/study/NCT04727723","created_at":"2021-02-11T16:55:44.504Z","updated_at":"2024-07-02T16:35:43.900Z","phase":"","brief_title":"Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs","source_id_and_acronym":"NCT04727723 - REAL-LU","lead_sponsor":"Advanced Accelerator Applications","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive • SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive • SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 164","initiation":"Initiation: 03/09/2021","start_date":" 03/09/2021","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2023-07-06"},{"id":"37969cd9-a62c-4486-b4a3-d4e0ab0714cd","acronym":"P-PRRT","url":"https://clinicaltrials.gov/study/NCT02754297","created_at":"2021-01-18T13:30:07.753Z","updated_at":"2024-07-02T16:35:46.711Z","phase":"Phase 2","brief_title":"Personalized PRRT of Neuroendocrine Tumors","source_id_and_acronym":"NCT02754297 - P-PRRT","lead_sponsor":"CHU de Quebec-Universite Laval","biomarkers":" SSTR • CHGA","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 04/12/2016","start_date":" 04/12/2016","primary_txt":" Primary completion: 04/12/2025","primary_completion_date":" 04/12/2025","study_txt":" Completion: 04/12/2029","study_completion_date":" 04/12/2029","last_update_posted":"2023-06-01"},{"id":"d0afaa59-8d9c-43d9-b962-8180fb565843","acronym":"","url":"https://clinicaltrials.gov/study/NCT03273712","created_at":"2021-02-11T16:53:25.958Z","updated_at":"2024-07-02T16:35:55.943Z","phase":"Phase 2","brief_title":"Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)","source_id_and_acronym":"NCT03273712","lead_sponsor":"University of Iowa","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 09/29/2017","start_date":" 09/29/2017","primary_txt":" Primary completion: 05/27/2020","primary_completion_date":" 05/27/2020","study_txt":" Completion: 05/27/2020","study_completion_date":" 05/27/2020","last_update_posted":"2023-02-09"},{"id":"fd27eba5-070d-465c-9dd7-90afaae4e124","acronym":"PV-10-NET-01","url":"https://clinicaltrials.gov/study/NCT02693067","created_at":"2021-02-11T16:53:11.341Z","updated_at":"2024-07-02T16:35:56.153Z","phase":"Phase 1","brief_title":"A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver","source_id_and_acronym":"NCT02693067 - PV-10-NET-01","lead_sponsor":"Provectus Biopharmaceuticals, Inc.","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Provecta (rose bengal sodium)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 09/01/2021","primary_completion_date":" 09/01/2021","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2023-02-08"},{"id":"81498a4c-038d-488e-857c-348cb81a2810","acronym":"","url":"https://clinicaltrials.gov/study/NCT03478358","created_at":"2021-02-11T16:53:34.239Z","updated_at":"2024-07-02T16:36:04.680Z","phase":"Phase 1","brief_title":"Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors","source_id_and_acronym":"NCT03478358","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • 177Lu-EBTATE • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/30/2017","start_date":" 04/30/2017","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 05/01/2023","study_completion_date":" 05/01/2023","last_update_posted":"2022-08-31"},{"id":"e8812a83-2fdb-4543-9574-940603d3b774","acronym":"","url":"https://clinicaltrials.gov/study/NCT02810600","created_at":"2021-02-11T16:53:14.707Z","updated_at":"2024-07-02T16:36:30.068Z","phase":"Phase 2","brief_title":"Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors","source_id_and_acronym":"NCT02810600","lead_sponsor":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"],"overall_status":"Completed","enrollment":" Enrollment 2120","initiation":"Initiation: 06/08/2016","start_date":" 06/08/2016","primary_txt":" Primary completion: 01/01/2020","primary_completion_date":" 01/01/2020","study_txt":" Completion: 05/29/2020","study_completion_date":" 05/29/2020","last_update_posted":"2021-05-18"},{"id":"2c505dcd-09e5-4284-9e05-a7a8505e815b","acronym":"FENET-2016","url":"https://clinicaltrials.gov/study/NCT04790708","created_at":"2021-03-10T12:54:51.502Z","updated_at":"2024-07-02T16:36:33.460Z","phase":"","brief_title":"Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2)","source_id_and_acronym":"NCT04790708 - FENET-2016","lead_sponsor":"University Hospital of Ferrara","biomarkers":" mTOR • SSTR • UBR5","pipe":" | ","alterations":" SSTR Expression","tags":["mTOR • SSTR • UBR5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 07/02/2018","start_date":" 07/02/2018","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 06/30/2023","study_completion_date":" 06/30/2023","last_update_posted":"2021-03-10"}]